今日の臨床サポート 今日の臨床サポート
関連論文:
img  2:  New non-contrast MRI of endolymphatic hydrops in Ménière's disease considering inversion time.
 
著者: Ishii M, Tanaka H, Asai R, Kanai Y, Kato Y, Ito Y, Mochizuki F, Yoneyama M, Ishiyama G, Ishiyama A.
雑誌名: Laryngoscope Investig Otolaryngol. 2024 Aug;9(4):e1314. doi: 10.1002/lio2.1314. Epub 2024 Aug 10.
Abstract/Text OBJECTIVES: Three-tesla MRI with gadolinium-based contrast agents is important in diagnosing Ménière's disease. However, contrast agents cannot be used in some patients. By using the compositional difference between the inner ear endolymph and perilymph, we performed basic and clinical research focused on potassium ions and protein to find the optimal parameters for visualizing endolymphatic hydrops on MRI without contrast. We then examined the relationship between severity stage and visualization rate of endolymphatic hydrops.
METHODS: In phantom experiments simulating the endolymph and perilymph, we explored MRI parameters that could be used to separate endolymph from perilymph by gradually changing the inversion time. We then used these parameters to perform both new non-contrast MRI and contrast MRI on the same day in Ménière's disease patients, and we compared the visualization rates of endolymphatic hydrops under the two modalities. Fifty patients were selected from 478 patients with Ménière's disease of different severity stages; 12 patients had asthma and allergy to contrast agents.
RESULTS: The higher the disease stage, the higher the endolymphatic hydrops visualization rate. The new non-contrast MRI gave significantly higher (p < .01) visualization rates of endolymphatic hydrops on the affected side in patients at Stage 3 or above than in Stages 1 and 2 combined.
CONCLUSION: New non-contrast MRI with parameters focusing on the endolymph-perilymph difference in the density of protons surrounding the potassium ions and protein can produce images consistent with endolymphatic hydrops. We believe that this groundbreaking method will be useful for diagnosing Ménière's disease in patients.
EVIDENCE LEVEL: Clinical studies are at evidence level 3 in non-randomized controlled trials.

© 2024 The Author(s). Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.
PMID 39130211  Laryngoscope Investig Otolaryngol. 2024 Aug;9(4):e1314. doi: 10.1002/lio2.1314. Epub 2024 Aug 10.
戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから